NCT03235219View on ClinicalTrials.gov

A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

February 19, 2018

Study Completion Date

February 19, 2018

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

JNJ-64565111

Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.

DRUG

Placebo

Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.

Trial Locations (2)

33147

Advanced Pharma CR, LLC, Miami

91911

ProSciento, Inc., Chula Vista

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03235219 - A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter